NCT03456908已完成1 期
F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Evaluate the uptake and distribution of the imaging agent 18F-TFB
研究概览
简要总结
The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. .
详细描述
The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. Imaging of functional hNIS activity in tissues with [18F]BF4 is anticipated to provide superior sensitivity and image quality to Tc-99m SPECT for monitoring hNIS transduction effected by viral therapies. The proposed work is designed to 1) evaluate the imaging feasibility in comparison with Tc-99m SPECT of hNIS expression in a) 10 myeloma patients treated with Edmonston Measles virus-NIS (MV-NIS) and b) 10 endometrial cancer patients treated with vesicular stomatitis virus engineered to express human interferon-and NIS (VSV-hINF-NIS). This data will be necessary to support future regulatory submissions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Myeloma Patients
- •Patients who are currently participating in Mayo Clinic MV-NIS trial (IRB: 06-005263) and agree to enroll in additional 18F-TFB PET studies.
- •Subjects are greater than 21 years of age.
- •Subjects must provide written informed consent.
- •Agree to provide biopsy of tumor indicated on PET for research purposes, if accessible.
- •Endometrial Cancer Patients
- •1 Patients who are currently participating in Mayo Clinic VSV-hINF-NIS trial (IRB 15-007000) and agree to enroll in additional 18F -TFB-PET studies.
- •Subjects are greater than 21 years of age.
- •Subjects must provide written informed consent.
- •Agree to provide biopsy of tumor indicated on PET for research purposes, if accessible.
排除标准
- •Myeloma Patients
- •Patients with any of the following are ineligible to enroll in this study:
- •Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:
- •Cardiac surgery or myocardial infarction within the last 6 months.
- •Unstable angina.
- •Coronary artery disease that required a change in medication within the last 3 months.
- •Decompensated congestive heart failure.
- •Significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status.
- •Severe mitral or aortic valvular disease.
- •Uncontrolled high blood pressure.
- •Congenital heart disease. Before enrolling a patient with any of the above conditions, the co- investigator must contact the principal investigator.
- •History of drug or alcohol abuse within the last year, or prior prolonged history of abuse.
- •Clinically significant infectious disease, including AIDS or HIV infection or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-
- •Women of childbearing potential must not be pregnant (negative urine β-HCG at the time of screen) or lactating over the course of the study. A commercial urine dipstick test will be performed within 48 hours prior to injection of 18F-TFB PET unless the screening urine pregnancy test falls within 48 hours of injection.
- •Patients who, in the opinion of the investigator, are otherwise unsuitable for a study of this type.
- •History of severe drug allergy or hypersensitivity.
- •Patients who had received an investigational medication within the last 30 days or who have participated in a clinical trial involving medications other than the related MV-NIS or VSV-NIS viruses in the last 30 days. Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication.
- •Patients with current clinically significant medical comorbidities that might pose a potential safety risk, interfere with the absorption or metabolism of the study medication, or limit interpretation of the study results. These include but are not limited to clinically significant hepatic, renal, pulmonary, metabolic or endocrine disease, cancer, HIV infection and AIDS.
- •Patients who are taking drugs with narrow therapeutic windows, such as theophylline, or warfarin, heparin and other anticoagulant therapies.
- •Endometrial Cancer Patients
- •Patients with any of the following are ineligible to enroll in this study:
- •Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:
- •Cardiac surgery or myocardial infarction within the last 6 months.
- •Unstable angina.
- •Coronary artery disease that required a change in medication within the last 3 months.
- •Decompensated congestive heart failure.
- •Significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status.
- •Severe mitral or aortic valvular disease.
- •Uncontrolled high blood pressure.
- •Congenital heart disease. Before enrolling a patient with any of the above conditions, the co- investigator must contact the principal investigator.
- •History of drug or alcohol abuse within the last year, or prior prolonged history of abuse.
- •Clinically significant infectious disease, including AIDS or HIV infection or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-
- •Women of childbearing potential must not be pregnant (negative urine β-HCG at the time of screen) or lactating over the course of the study. A commercial urine dipstick test will be performed within 48 hours prior to injection of 18F-TFB PET unless the screening urine pregnancy test falls within 48 hours of injection.
- •Patients who, in the opinion of the investigator, are otherwise unsuitable for a study of this type.
- •History of severe drug allergy or hypersensitivity.
- •Patients who had received an investigational medication within the last 30 days or who have participated in a clinical trial with any experimental medication in the last 30 days. Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication.
- •Patients with current clinically significant medical comorbidities, that might pose a potential safety risk, interfere with the absorption or metabolism of the study medication or limit interpretation of the study results. These include but are not limited to clinically significant hepatic, renal, pulmonary, metabolic or endocrine disease, cancer, HIV infection and AIDS.
- •Patients who are taking drugs with narrow therapeutic windows, such as theophylline, or warfarin, heparin and other anticoagulant therapies.
结局指标
主要结局
Evaluate the uptake and distribution of the imaging agent 18F-TFB
时间窗: up to 10 days
This is a preliminary study and all analyses will be exploratory in nature.
次要结局
- Imaging Sensitivities(up to 10 days)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
F-Tryptophan PET/CT in Human CancersIntracranial GliomaMetastatic Brain TumorNeuroendocrine TumorsRectal CancerBreast CancerNCT05556473Barbara Ann Karmanos Cancer Institute24
进行中（未招募）
2 期
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast CancerBreast CarcinomaNCT05226663M.D. Anderson Cancer Center36
撤回
早期 1 期
Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue SarcomaStage II Adult Soft Tissue SarcomaStage IIA Adult Soft Tissue SarcomaStage IIB Adult Soft Tissue SarcomaStage IIC Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue SarcomaNCT03613259OHSU Knight Cancer Institute
终止
不适用
FLT-PET Imaging for MDSMDSAMLNCT01535456University of Wisconsin, Madison1
进行中（未招募）
1 期
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)Solid MalignancyLymphomaNCT01697930Memorial Sloan Kettering Cancer Center67